Dissipating Excess Energy Stored in the Liver Is a Potential Treatment Strategy for Diabetes Associated With Obesity

• Yasushi Ishigaki

  Division of Molecular Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan

• Hideki Katagiri

  Division of Advanced Therapeutics for Metabolic Diseases, Center for Translational and Advanced Animal Research, Tohoku University Graduate School of Medicine, Sendai, Japan

• Tetsuya Yamada

  Division of Molecular Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan

• Takehide Ogihara

  Division of Advanced Therapeutics for Metabolic Diseases, Center for Translational and Advanced Animal Research, Tohoku University Graduate School of Medicine, Sendai, Japan

• Junta Imai

  Division of Molecular Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan

• Kenji Uno

  Division of Molecular Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan

• Yutaka Hasegawa

  Division of Molecular Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan

• Junhong Gao

  Division of Molecular Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan

• Hisamitsu Ishihara

  Division of Molecular Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan

• Tooru Shimosegawa

  Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan

• Hideyuki Sakoda

  Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Tokyo, Japan

• Tomoichiro Asano

  Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Tokyo, Japan

• Yoshitomo Oka

  Division of Molecular Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan

抄録

For examining whether dissipating excess energy in the liver is a possible therapeutic approach to high-fat diet–induced metabolic disorders, uncoupling protein-1 (UCP1) was expressed in murine liver using adenoviral vectors in mice with high-fat diet–induced diabetes and obesity, and in standard diet–fed lean mice. Once diabetes with obesity developed, hepatic UCP1 expression increased energy expenditure, decreased body weight, and reduced fat in the liver and adipose tissues, resulting in markedly improved insulin resistance and, thus, diabetes and dyslipidemia. Decreased expressions of enzymes for lipid synthesis and glucose production and activation of AMP-activated kinase in the liver seem to contribute to these improvements. Hepatic UCP1 expression also reversed high-fat diet–induced hyperphagia and hypothalamic leptin resistance, as well as insulin resistance in muscle. In contrast, intriguingly, in standard diet–fed lean mice, hepatic UCP1 expression did not significantly affect energy expenditure or hepatic ATP contents. Furthermore, no alterations in blood glucose levels, body weight, or adiposity were observed. These findings suggest that ectopic UCP1 in the liver dissipates surplus energy without affecting required energy and exerts minimal metabolic effects in lean mice. Thus, enhanced UCP expression in the liver is a new potential therapeutic target for the metabolic syndrome.

収録刊行物

• Diabetes

  Diabetes 54 (2), 322-332, 2005-02-01

  American Diabetes Association

キーワード

• Endocrinology, Diabetes and Metabolism
• Internal Medicine

詳細情報

• CRID: 1363388846255808768
• NII論文ID: 30026276289
• DOI: 10.2337/diabetes.54.2.322
• ISSN: 1939327X
• ISSN: 00121797
• Web Site: https://journals.org/diabetes/diabetes/article-pdf/54/2/322/655645/zdb00205000322.pdf
• Web Site: https://diabetesjournals.org/diabetes/article-pdf/54/2/322/655645/zdb00205000322.pdf
• データソース種別:
  • Crossref
  • CiNii Articles
  • KAKEN